Yeh Wei-Hsi, Shubina-Oleinik Olga, Levy Jonathan M, Pan Bifeng, Newby Gregory A, Wornow Michael, Burt Rachel, Chen Jonathan C, Holt Jeffrey R, Liu David R
Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
Sci Transl Med. 2020 Jun 3;12(546). doi: 10.1126/scitranslmed.aay9101.
Most genetic diseases arise from recessive point mutations that require correction, rather than disruption, of the pathogenic allele to benefit patients. Base editing has the potential to directly repair point mutations and provide therapeutic restoration of gene function. Mutations of transmembrane channel-like 1 gene () can cause dominant or recessive deafness. We developed a base editing strategy to treat Baringo mice, which carry a recessive, loss-of-function point mutation (; resulting in the substitution p.Y182C) in Tmc1 that causes deafness. encodes a protein that forms mechanosensitive ion channels in sensory hair cells of the inner ear and is required for normal auditory function. We found that sensory hair cells of Baringo mice have a complete loss of auditory sensory transduction. To repair the mutation, we tested several optimized cytosine base editors (CBEmax variants) and guide RNAs in Baringo mouse embryonic fibroblasts. We packaged the most promising CBE, derived from an activation-induced cytidine deaminase (AID), into dual adeno-associated viruses (AAVs) using a split-intein delivery system. The dual AID-CBEmax AAVs were injected into the inner ears of Baringo mice at postnatal day 1. Injected mice showed up to 51% reversion of the point mutation to wild-type sequence () in transcripts. Repair of in vivo restored inner hair cell sensory transduction and hair cell morphology and transiently rescued low-frequency hearing 4 weeks after injection. These findings provide a foundation for a potential one-time treatment for recessive hearing loss and support further development of base editing to correct pathogenic point mutations.
大多数遗传疾病源于隐性点突变,需要纠正而非破坏致病等位基因才能使患者受益。碱基编辑有直接修复点突变并恢复基因功能的治疗潜力。跨膜通道样蛋白1基因(Tmc1)突变可导致显性或隐性耳聋。我们开发了一种碱基编辑策略来治疗巴林戈小鼠,这些小鼠携带Tmc1基因中的隐性功能丧失点突变(c.545A>G;导致p.Y182C替换),该突变会导致耳聋。Tmc1编码一种在内耳感觉毛细胞中形成机械敏感离子通道的蛋白质,是正常听觉功能所必需的。我们发现巴林戈小鼠的感觉毛细胞完全丧失了听觉感觉转导。为了修复该突变,我们在巴林戈小鼠胚胎成纤维细胞中测试了几种优化的胞嘧啶碱基编辑器(CBEmax变体)和引导RNA。我们使用分裂内含肽递送系统将源自激活诱导胞苷脱氨酶(AID)的最有前景的CBE包装成双腺相关病毒(AAV)。在出生后第1天将双AID-CBEmax AAV注射到巴林戈小鼠的内耳中。注射后的小鼠在Tmc1转录本中显示高达51%的点突变回复为野生型序列(c.545A)。体内Tmc1的修复恢复了内毛细胞的感觉转导和毛细胞形态,并在注射后4周短暂恢复了低频听力。这些发现为隐性听力损失的潜在一次性治疗提供了基础,并支持碱基编辑在纠正致病点突变方面的进一步发展。